Insider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Director Sells 6,075 Shares of Stock

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) Director Jeffrey S. Flier sold 6,075 shares of the business's stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $29.73, for a total value of $180,609.75. Following the completion of the transaction, the director now owns 24,070 shares in the company, valued at approximately $715,601.10. This trade represents a 20.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Scholar Rock Stock Down 2.4%

NASDAQ SRRK traded down $0.71 on Friday, hitting $29.13. 1,368,000 shares of the stock traded hands, compared to its average volume of 1,270,141. The stock has a 50-day moving average of $30.38 and a 200 day moving average of $36.04. Scholar Rock Holding Co. has a twelve month low of $6.76 and a twelve month high of $46.98. The company has a market capitalization of $2.77 billion, a P/E ratio of -12.40 and a beta of 0.37. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter in the previous year, the business posted ($0.59) earnings per share. As a group, analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wedbush reiterated an "outperform" rating and issued a $50.00 price target on shares of Scholar Rock in a research note on Wednesday, May 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $42.67.

Institutional Trading of Scholar Rock

Institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC raised its stake in Scholar Rock by 152.8% during the first quarter. CWM LLC now owns 996 shares of the company's stock valued at $32,000 after buying an additional 602 shares in the last quarter. Global Retirement Partners LLC raised its position in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after purchasing an additional 766 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after purchasing an additional 1,031 shares during the period. Federated Hermes Inc. acquired a new stake in shares of Scholar Rock during the 1st quarter worth approximately $71,000. Finally, GF Fund Management CO. LTD. raised its position in shares of Scholar Rock by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company's stock worth $77,000 after purchasing an additional 430 shares during the period. Institutional investors and hedge funds own 91.08% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.